



GUTBRAIN

Axis 2018

Le Méridien Etoile Paris | 6 – 7 September



DESCRIPTION

On 06 & 07 September 2018, Paris will host the BioTech Pharma Summit: Gut-Brain Axis 2018 conference. The event brings together leading scientists, physicians, and senior leaders to explore the brain and its engagement with the GI-nervous system in health and disease.

The ability of gut microbiota to communicate with the brain is emerging as an exciting concept in health and disease. Mounting evidence, mostly from rodent studies, suggests that gut microbes help shape normal neural development, brain biochemistry, and behaviour.

The BioTech Pharma Summit: Gut-Brain Axis 2018 will be dedicated to help large pharma, biotech, academics and clinicians exploring and understand the GBA in health and disease.

KEY PRACTICAL LEARNING POINTS

- ◆ Effectively understand and manipulate the Gut-Brain Axis
- ◆ Learn about the microbiota and their metabolites and neurotransmitters production
- ◆ The impact of environment and age on shaping our individual microbiota
- ◆ Discover tools and technologies to help investigate the GBA
- ◆ Build predictive pre-clinical models in the gut-brain axis
- ◆ Role that the GI microbiome plays in modulating the immune system and the GI-brain axis
- ◆ Current options for prevention, diagnosis and treatment of neurodegenerative, metabolic and autoimmune disorders
- ◆ The importance of the gut-brain axis in emotional, behavioral and development disorders
- ◆ Stress related bowel disease: gut-brain axis in IBD and IBS
- ◆ Develop commercially viable therapeutics and nutritional products
- ◆ Probiotics, prebiotics, synbiotics and psychobiotics



WHO SHOULD ATTEND?

**CEOs, VPs, Drug developers, Academics and Researchers,
CROs, Scientists and Medical Doctors including:**

- › Endocrinologists and Diabetologists,
- › Gastroenterologists, Psychiatrists Medical Immunology
- › and Microbiology
- › Medical Advisor
- › Neuroscientist
- › Integrative & Experimental Pathology
- › Drug Discovery
- › Regulatory Affairs
- › Medicinal Chemistry & CMC
- › Associate Research Director
- › Strategy & Business
- › IVD Assay Development
- › Safety Risk Lead
- › Preclinical Group Leader
- › Pharmacovigilance
- › Medical Information Manager
- › Research Investigator
- › Physiologists
- › Scientific Project Leader
- › Head Search & Evaluation Neuroscience
- › Molecular Toxicology
- › Nutrition & Health
- › Laboratory Director
- › Modeling and Data Specialist
- › Microbiome and Lipid Biology
- › Genome Editing

The Gut-Brain Axis 2018 is set to be the “must-attend” meeting for anyone interested in unlocking the potential of the gut-brain axis, and translating it into safe, effective and commercially viable therapeutics.

With 23+ expert speakers, 20+ case studies demonstrating the interactions between gut microbiota and brain in disorders of brain gut interactions.



S P E A K E R S



BIRGITTE HOLST

Prof. MSO, Biomedical Sciences/NNF Center for Basic Metabolic Research, Uni. of Copenhagen

DK



BRUNO BONAZ

Professor of Gastroenterology in the Grenoble Faculty of Medicine and Hospital in France

FR



TED DINAN

Professor of Psychiatry and a Principal Investigator in the APC Microbiome Institute

IE



ROCHELLYS DIAZ HEIJTZ

Associate Professor and Group Leader in the Department of Neuroscience at Karolinska Institutet

SE



SARKIS K. MAZMANIAN

Caltech and Heritage Medical Research Institute

USA



NIKOLAOS VENIZELOS

Professor, Head of the Neuropsychiatric Research Laboratory at Örebro University

SE



MARTHA WELCH

Director of the Nurture Science Program in Pediatrics at Columbia University Medical Center

USA



DAVID FINKELSTEIN

Head, Parkinson's Disease Laboratory at Florey Institute, University of Melbourne

AU



SERGUEI FETISSOV

Professor of Physiology at Rouen University and Co-Founder of TargEDys

FR



CHRISTOPHER REYES

Chief Scientific Officer and co-founder at Bloom Science

USA



KOEN VENEMA

Founder & CEO of Beneficial Microbes Consultancy and Chair in Gut Microbiology at Maastricht University

NL



DERRICK MACFABE

Director of the Kilee Patche-II-Evans Autism Research Group

CA



RUTH ANN LUNA

Assistant Professor, Director of Medical Metagenomics in the Texas Children's Microbiome Center

USA



WOUTER DE JONGE

Professor of Neurogastroenterology at AMC, CoFounder of Gut Research

NL



ROBERT BRUMMER

Professor, Director of Nutrition-Gut-Brain Interactions Research Centre, Örebro University

SE



MARION SOTO

Project leader at LNC Therapeutics

FR

With 23+ expert speakers, 20+ case studies demonstrating the interactions between gut microbiota and brain in disorders of brain gut interactions.



PATRICE GARNIER
CEO at Amabiotics

FR



PHILIP STRANDWITZ
Co-Founder and
CEO at Holobiome

USA



MAGALI CORDAI-LLAT-SIMMONS
Scientific and
Regulatory Affairs
Director at Phar-
mabiotic Research
Institute (PRI)

FR



SHAHRAM LAVASANI
Founder and CEO
at ImmuneBiotech
AB

SE



GEORGE WEINSTOCK
Professor, Director
of Microbial Geno-
mics at Jackson
Laboratory

USA

A blurred background image showing a group of people in a meeting or collaborative work environment. The image is overlaid with a semi-transparent blue filter. A white rectangular box is positioned in the center, containing the text 'SCIENTIFIC AGENDA' in white, uppercase, sans-serif font.

SCIENTIFIC AGENDA

08:00 Registration and Welcome Coffee

08:50 Opening Ceremony

GUT-BRAIN AXIS: CURRENT AND FUTURE PERSPECTIVES

09:00 Knowledge and knowledge Gaps in GBA

By **Robert JM Brummer** - Örebro University / Nutrition-Gut-Brain Interactions Research Centret

- › Perspective of the various stakeholders (scientist, consumers, industry, clinic/ public health)
- › What are the essential questions we have to answer about GBA as a prerequisite for future radical developments and applications?
- › Is the traditional Randomised Clinical Trial the adequate way to prove new applications of functional foods in GBA perspective?

09:30 Speed Networking

10:00 Morning Coffee and Networking Break

10:30 Microbiome Past, Present, and Future

By **George Weinstock** - Jackson Laboratory

- › Integration of data on host, microbiome, and environment in analysis
- › Importance of model systems
- › Influence of host genetics

11:00 **Panel Discussion:** The Challenges of a Growing Field

By **Magali Cordaillat-Simmons** - Pharmabiotic Research Institute (PRI)

TARGETING THE MICROBIOTA METABOLITES AND NEUROTRANSMITTERS

11:30 Enteric Short Chain Fatty Acids - Microbial Modulators of Metabolism, Mitochondria and Mind

By **Derrick MacFabe** - Kilee Patchell-Evans Autism Research Group

12:00 Effects of Foods and Drugs on SCFA Production by the Gut Microbiota and How this Relates to the Gut-Brain Axis

By **Koen Venema** - Maastricht University and Beneficial Microbes Consultancy

- › Production of SCFA by the gut microbiota
- › Relation of SCFA to the gut-brain axis
- › Modulation of the gut microbiota (composition and activity) using the TNO in vitro model of the colon

12:30 Neurotransmission and the Human Gut Microbiota

By **Philip Strandwitz** - Holobiome

- › How the microbiota appears to influence the central and enteric nervous systems
- › Which neurotransmitters are modified by the microbiota
- › How to consider drugging these systems

13:00 Business Lunch

MICROBIOTA IN GASTROINTESTINAL ISSUES

14:00 *To be Defined*

-

14:30 **The Vagus Nerve and its Inflammatory Role in the (Microbiota)-Brain-Gut Axis**

By **Bruno Bonaz** - Grenoble Institute of Neurosciences / Cerebral Stimulation & Systems Neuroscience

- › The vagus nerve at the interface of the microbiota-brain-gut axis
- › The anti-inflammatory role of the vagus nerve
- › Vagus nerve stimulation as a non-drug therapy of gut inflammatory disorders (and others)

15:00 **Bioelectronic Medicine: Principle and Feasibility**

By **Wouter de Jonge** - Academic Medical Center / Department of Gastroenterology

- › Depending on disease and organ involved, recent data indicate a critical role for sympathathetic nerves (that innervate lymphoid organs) to regulate gut immunity
- › The clinical utilization of the innovative principle of bioelectronic medicine is directly within reach, as implantable devices to treat chronic disease are already FDA approved and tested in pioneering trials of vagal nerve stimulation (VNS) that may be applied to other neurons; Next research should focus on the mechanism of action of this type of therapy allowing the implementation of Bioelectronics as medicine-free treatment in chronic inflammatory diseases
- › Sympathetic activity gives rise to newly identified effector T lymphocytes that are particularly responsive to neuronal activity leading us to hypothesize that sympathetic nerve activity is a critical regulator of immune homeostasis and immune defense in the gut

METABOLISM IN MIND: NEW APPROACHES REGARDING THE GUT-BRAIN AXIS

15:30 **Gut Microbiota and Host Motivated Behavior**

By **Sergueï O. Fetissov** - Rouen University and TargEDys

- › Motivated behavior is regulated in the brain under influence of peripheral factors signaling the body metabolic state
- › Gut bacteria use the host for the regular nutrient supply maintaining stable bacterial population
- › Molecular mechanisms linking gut bacteria with the brain are involved in the regulation of host motivated behavior
- › New microbiota-based approaches can be designed to influence host motivated behavior

16:00 **Coffee Break**

16:30 **Neurotensin – An Overlooked Gut-Hormone Regulating Appetite**

By **Birgitte Holst** - University of Copenhagen / Dep. Biomedical Sciences and NNF Center for Basic Metabolic Research

- › Regulation during gastric bypass surgery
- › Appetite regulation
- › Potential co-administration with GLP-1

17:00 **Interactions Between Gut Microbiota and Brain in Metabolic Diseases**

By **Marion Soto** - LNC Therapeutics

- › Gut microbiome is altered in metabolic diseases
- › How the modulations in microbiome composition associated with type 2 diabetes and obesity lead to insulin resistance in the brain and to defects in metabolism, cognition and behavior
- › How knowledge of the gut-brain axis crosstalk can lead to new therapeutics to treat metabolic diseases

17:30 **Chairman's Closing Remarks**

20:00 **Gala Dinner**

08:30 Registration and Welcome Coffee

GBA IN EMOTIONAL, BEHAVIORAL AND DEVELOPMENT DISORDERS

09:00 Gut Microbes and the Developing Brain

By **Rochellys Diaz Heijtz** - Karolinska Institutet / Department of Neuroscience

- › Microbiota influence brain development and behavior
- › Commensal bacteria-derived products can be translocated into the brain under normal conditions and influence the developing brain
- › Discussing novel roles of bacterial peptidoglycan sensing molecules on brain development and behavior

09:30 It's All About Nurture: Gut-Brain Peptides, Inflammation, and Emotional and Behavioral Disorders

By **Martha G. Welch** - Columbia University Medical Center / Nurture Science Program in Pediatrics

- › The role of colostrum oxytocin in the newborn gut villi-modulation of cell stress response, inflammation and autophagy
- › Oxytocinergic cell signaling pathways in the gut-brain axis
- › The role of oxytocin and secretin in gut inflammation and the stress signaling pathway
- › Defining "nurture" from the bottom-up -The role of the autonomic nervous system in co-regulation of physiology and behavior
- › Testing theoretical hypotheses at the bench and at the bedside
- › Capitalizing on the molecular mechanisms of nurture

10:00 Multi-omic Characterization of the Microbiome-Gut-Brain Axis in Autism Spectrum Disorder

By **Ruth Ann Luna** - Baylor College of Medicine and Texas Children's Microbiome Center

- › Microbiome-neuroimmune signatures correlate with abdominal pain in ASD
- › Findings from a large pediatric ASD cohort that includes the gut microbiome/metabolome and both gastrointestinal and behavioral phenotypes highlight the heterogeneity of ASD
- › Longitudinal case study has linked GI exacerbations, behavior, and changes in the gut microbiome
- › Pilot probiotic trial in pediatric ASD provides additional case studies on potential therapeutics

10:30 Coffee Break

INVOLVEMENT OF THE MICROBIOTA IN NEUROLOGICAL & PSYCHIATRIC DISORDERS

11:00 Brain-Gut-Microbiota Axis: A Target for Stress Related Disorders

By **Ted Dinan** - APC Microbiome Institute at University College Cork

- › Gut microbes communicate with the brain through various channels including the vagus nerve and short chain fatty acids
- › The gut microbiota is altered in stress related disorders such as depression
- › Psychobiotics, such as *Bifidobacterium longum* 1714, have been shown to reduce stress levels, improve cognitive functioning and alter brain electrophysiology

11:30 Harnessing the Therapeutic Potential of Commensal Microbes for the Treatment for Human Epilepsy

By **Christopher Reyes** - Bloom Science

- › Select bacteria are sufficient to mediate seizure protective effects
- › Bacterial treatment is effective for varied seizure types and origins
- › Biochemical interactions between bacteria modulate metabolites that regulate brain neurotransmitters

12:00 Proinflammatory Cytokines and Oxidative Stress Can Cause Cognitive Dysfunction in Schizophrenia, Bipolar Disorders, and Related CNS Diseases

By **Nikolaos Venizelos** - Örebro University / Neuropsychiatric Research Laboratory & Biobank

- Evidence that the pro-inflammatory cytokines and oxidative stress affect the functionality of neurotransmitter precursor amino acid transporters (the uptake of tyrosine and tryptophan significantly inhibits up 47%)
- Changes in the dopaminergic and serotonergic brain systems can lead to deterioration of, among others, the cognition and behavior in patients with schizophrenia, bipolar disorders, and related CNS diseases

12:30 Panel Discussion: To be Defined

-

13:00 Lunch Break

THERAPEUTICAL EFFORTS TARGETING THE GUT-BRAIN AXIS

14:00 Fecal Microbiota Transplants (FMTs) Have Shown Great Clinical Success in Recurrent C. difficile Infections. May This Approach Have Efficacy in Regulating the Gut-Brain Axis?

By **Sarkis K. Mazmanian** - California Institute of Technology (Caltech) and Heritage Medical Research Institute

- What are key microbiome and biological differences between C. difficile infections and neurological disorders that may provide insight into common or different mechanisms of action for FMT?
- Would pretreatment with antibiotics be required for FMTs to be effective in neurological conditions?
- While limited treatment of C. difficile appears to work, will FMTs for neurological disorders require chronic (perhaps lifelong) treatment?

14:30 To be Defined

By **Shahram Lavasani** - ImmuneBiotech AB

15:00 Coffee Break

15:30 Developing Therapeutics for the Gastrointestinal Problems in Parkinsons Disease

By **David Finkelstein** Florey Institute of Neuroscience and Mental Health, University of Melbourne / Parkinson's Disease Laboratory

- Constipation and malabsorption in Parkinsons Disease are problems that effects the quality of life of most people living with Parkinsons
- Gut problems in Parkinsons do not have effective therapies
- It is uncertain if the problems with gut originate in the brain or the gut
- Compounds that alter alpha-synuclein toxicity have a benefit for gut function

16:00 From Microbiome Explorations to Effective Innovative Therapies in Parkinson Disease: a case study

By **Patrice Garnier** - Amabiotics

- From biochemical mechanisms to proof of concept: how to design a new microbiome-oriented strategy for Parkinson Disease
- Preclinical and clinical trials: the same road as pharmaceutical development?

**16:30 Chairman's Closing Remarks
End of Summit**

**BIRGITTE HOLST**

Prof. MSO, Biomedical Sciences/NNF Center for Basic Metabolic Research, Uni. of Copenhagen



Birgitte Holst, MD, PhD, Professor MSO in Metabolic and Molecular Pharmacology, Founder and Head of Rodent Metabolic Phenotyping Center and Group leader of the Novo Nordisk Foundation Center for Basic Metabolic Research. For the last more than 10 years, Prof. Birgitte Holst group has been working with the molecular pharmacology of G-protein coupled receptor involved in endocrine regulation. Most focus has been on Gut hormone receptors and its signalling properties such as biased signalling and constitutive activity and how these properties translate into in vivo functions for metabolic diseases. The rodent metabolic phenotyping center is currently a "melting pot" for all researchers working in the metabolic field at the University of Copenhagen, giving rise to scientific innovation and collaborations across the different sections of the CBMR, but also with other parts of the University.

**TED DINAN**

Professor of Psychiatry and a Principal Investigator in the APC Microbiome Institute



Ted Dinan is Professor of Psychiatry and a Principal Investigator in the APC Microbiome Institute at University College Cork. He was previously Chair of Clinical Neurosciences and Professor of Psychological Medicine at St. Bartholomew's Hospital, London. Prior to that, he was a Senior Lecturer in Psychiatry at Trinity College Dublin. He has worked in research laboratories on both sides of the Atlantic and has a PhD in Pharmacology from the University of London. He is a Fellow of the Royal Colleges of Physicians and Psychiatrists and a Fellow of the American College of Physicians.

**SARKIS K. MAZMANIAN**

Caltech and Co-Founder Axial Biotherapeutics



Sarkis K. Mazmanian, PhD, is the Luis & Nelly Soux Professor of Microbiology in the Division of Biology & Biological Engineering at the California Institute of Technology (Caltech), and an Investigator of the Heritage Medical Research Institute. He was a Phi Beta Kappa graduate from the University of California, Los Angeles, where Dr. Mazmanian also received his PhD training in microbiology and immunology. He was awarded a Helen Hay Whitney Postdoctoral Fellowship, and subsequently appointed Assistant Professor at Harvard Medical School before moving to Caltech in 2006. Dr. Mazmanian's laboratory focuses on the study of beneficial bacterial molecules from the human gut microbiome as novel therapies for immunologic and neurologic disorders, with a specific focus on developing probiotic treatments for inflammatory bowel disease, autism and Parkinson's disease. Dr. Mazmanian has won numerous awards including a Searle Scholar, Young Investigator of the Year at Harvard Medical School, Damon Runyon Innovation Award, was named by Discover Magazine as one of the "Best Brains in Science under 40", "Life Science Superstar" by Genetic Engineering and Biotechnology News, and recently received the MacArthur Foundation "Genius" award.

**BRUNO BONAZ**

Professor of Gastroenterology in the Grenoble Faculty of Medicine and Hospital in France



Bruno Bonaz MD, PhD, is a Professor of Gastroenterology in the Grenoble Faculty of Medicine and Hospital in France. He is a member of the team "Cerebral Stimulation & Systems Neuroscience" at the Grenoble Institute of Neurosciences (GIN, and was previously the team leader of the group Stress and Neurodigestive Interactions at the GIN. Prof. Bruno Bonaz work on brain-gut interactions for more than thirty years, both at the pre-clinical and clinical level, focusing on irritable bowel syndrome and inflammatory bowel diseases with a special interest on the role of stress and the autonomic nervous system in the physiopathology of such diseases. In particular, he is working on the anti-inflammatory (anti-TNF) properties of the vagus nerve (VN) through VN stimulation (VNS). He is presently the President of the International Society of Autonomic Neuroscience (ISAN).

**ROCHELLYS DIAZ HEIJTZ**

Associate Professor and Group Leader in the Department of Neuroscience at Karolinska Institutet



Dr. Rochellys Diaz Heijtz is an Associate Professor and Group Leader in the Department of Neuroscience at Karolinska Institutet. Her research studies have a long-term goal of understanding the biological basis of neurodevelopmental disorders (ASD, ADHD), and how genes and the environment (prenatal and/or early postnatal) together influence typical and atypical brain development and behavior. Her current research program includes basic studies investigating the influence of gut-derived microbial molecules, such as "bacterial peptidoglycan fragments" and their sensing molecules, on brain development and behavior, and clinical studies investigating the potential role of the gut microbiota in the pathophysiology of autism spectrum disorder (ASD) and other neurodevelopmental disorders.

**NIKOLAOS VENIZELOS**

Professor, Head of the Neuropsychiatric Research Laboratory at Örebro University



Prof. Nikolaos Venizelos studied biomedicine at Uppsala University in Sweden, a Master thesis in clinical chemistry & physiology and a PhD in Medicine at the Karolinska Institutet. Prof. Venizelos's conduct research in Experimental Neuropsychiatry with actual focus to explore the role and regulatory mechanisms of proinflammatory cytokines, environmental lifestyles stress factors, and the influence of probiotics on the transport of the neurotransmitter precursor's tyrosine and tryptophan in neuropsychiatric disorders and in the ageing process. Prof. Venizelos has been awarded with the "Norage-Pharmacia Award", and 2016 was awarded with the "Delphic Prize for Outstanding Contributions to Psychiatry and Related Sciences".

BIOGRAPHIES



MARTHA WELCH

Director of the Nurture Science Program in Pediatrics at Columbia University Medical Center



Dr. Welch is Director of the Nurture Science Program in Pediatrics at Columbia University Medical Center. A neuroscientist and clinician with 40+ years of experience working with children with developmental disorders. Dr. Welch is Associate Professor of Psychiatry in Pediatrics and Pathology & Cell Biology. From her clinical career, she developed a deep understanding of the central role of mother/infant interactions in infant and child development. For the past 21 years, she has led the design, conduct and analysis of studies involving both animal models and human infants. The work spans basic and clinical research to investigate the effects and mechanisms of nurture, including how oxytocin, affiliative behaviors and brain-gut function impact brain development. The overarching goal of the work has been to understand the impact of nurture on mother-infant co-regulation and emotional connection as well as on neurodevelopment.



SERGUEI FETISSOV

Professor of Physiology at Rouen University and Co-Founder of TargEDys



Sergueï O. Fetissov MD, PhD, was graduated from Military Medical Academy in St Petersburg and received his PhD from Institute of Developmental Biology of Russian Academy of Science in Moscow combined with training in Pierre & Marie Curie University in Paris. He worked as a researcher and principle investigator for more than 20 years in the field of physiology, neuroscience and nutrition in academic institutions including College de France in Paris, Upstate Medical University in Syracuse, USA and Karolinska Institutet in Stockholm, Sweden. From 2004, he is a professor of physiology at Rouen University, France affiliated to Inserm. He is a co-founder of TargEDys, SA a company developing solutions for eating dysfunction and obesity based on modulation of microbiome.



KOËN VENEMA

Founder & CEO of Beneficial Microbes Consultancy and Chair in Gut Microbiology at Maastricht University



Prof. Venema studied Chemistry at the University of Groningen, The Netherlands in 1990. He received his PhD in Natural Sciences from the same university, on the antimicrobial activity of bacteriocins produced by lactic acid bacteria (LAB) in 1995. He pursued the health-beneficial activity of these microbes as a Post-Doc at North Carolina State University, Raleigh, USA, where he studied the potential of LAB to function as carrier for vaccines. Thereafter, in 1998 he was employed by TNO for > 15 years, where he used the sophisticated, dynamic, computer-controlled in vitro models of the gastro-intestinal tract developed by TNO to study the effect of functional foods and drugs on bioavailability and effects on the colonic microbiota. Since Sept. 01, 2014 he runs a newly established research group at the University Maastricht – campus Venlo. Particularly, he studies the effect of interventions on the production of short-chain fatty acids (SCFA) and their role in health and disease.



DAVID FINKELSTEIN

Head, Parkinson's Disease Laboratory at Florey Institute, University of Melbourne



Since graduating with a PhD in Physiology, have worked to translate knowledge from fundamental science projects to provide clinical applications. Initially the research interests were centred on the physiology of control of movement, age related neurodegeneration and regeneration. Have subsequently used this basic science knowledge and applied it into developing novel therapeutic avenues for the treatment of Parkinson's disease and Parkinsonism. Based on is knowledge and expertise, was invited to be scientific consultant for two biotech companies, Prana Biotechnology Ltd (2006-ongoing) and Procyria Biotechnology Ltd (2009-2012), as well as international companies, Commonwealth Serum laboratories (2009-2012) and the Collaborative Medicinal Development LLC, USA (2013-present). He is the Chair of the Board of Parkinson's Victoria.



CHRISTOPHER REYES

Chief Scientific Officer and co-founder at Bloom Science



Dr. Christopher Reyes is Chief Scientific Officer and co-founder at Bloom Science, a biotechnology company focused on dramatically improving the lives of patients. Dr. Reyes is a biophysicist and entrepreneur with a passion for creating solutions to improve our health, environment and economic sustainability. He has founded two companies focused on developing therapeutics to address serious medical needs as well as a tech company focused on connecting people to socially conscious commerce solutions. Has a Ph.D. in Biophysics at the University of California, San Francisco and B.A. in Molecular and Cell Biology, Biophysics from the University of California, Berkeley.



DERRICK MACFABE

Director of the Kilee Patchell-Evans Autism Research Group



Since 2003, Dr. MacFabe has been Assistant Professor and Director of the Kilee Patchell-Evans Autism Research Group, Depts. of Psychology (Neuroscience) & Psychiatry (Division of Developmental Disabilities), at the Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada. He is also a Core Member of the iTARGET Autism Initiative, University of British Columbia, Vancouver. Dr. MacFabe is currently a Visiting Professor, Centre for Healthy Living and Food Innovation (HEFI), Faculty of Medicine, Maastricht University, Netherlands. Dr. MacFabe was awarded the Max Bramer Award from the American Academy of Developmental Medicine and Dentistry and Special Olympics and a recent recipient of the Mark Bieber Award from the American College of Nutrition and is a member of their Board of Directors.

**RUTH ANN LUNA**

Assistant Professor, Director of Medical Metagenomics in the Texas Children's Microbiome Center



Dr. Ruth Ann Luna serves as Assistant Professor in the Department of Pathology & Immunology at Baylor College of Medicine (BCM) and Director of Medical Metagenomics in the Texas Children's Microbiome Center (TCMC) at Texas Children's Hospital. She also serves as director of the Clinical Metagenomics Fellowship as well as a member of the Institutional Review Board at BCM. Dr. Luna's primary research focus is the microbiome-gut-brain axis in autism spectrum disorder (ASD), and her research has successfully linked GI symptoms, behavior, and the microbiome in ASD. Dr. Luna's work emphasizes a multi-omic approach to research- combining the microbiome, metabolome, and a variety of clinical data to better understand the underlying biology.

**ROBERT BRUMMER**

Professor, Director of Nutrition-Gut-Brain Interactions Research Centre, Örebro University



Robert Brummer studied medicine at Nijmegen University and was later appointed as resident physician at the Department of Clinical Nutrition, Göteborg University and Hospital. Subsequently, continued clinical training at the Department of Medicine, Maastricht, and was registered senior consultant in Internal medicine, Gastroenterology and Hepatology. In 1992, obtained a PhD in Medicine at Göteborg University. Became head of the GI-Motility Lab at the Department of Gastroenterology, University Hospital Maastricht and concomitantly was chief physician of the MedPsych Ward. In 2008 he joined Örebro University and University Hospital as professor Gastroenterology and Clinical Nutrition and contributed to establish a new Medical Faculty as Dean 2010-2016. He raised and directs the Nutrition-Gut-Brain Interactions Research Centre and was appointed Pro-Vice-Chancellor Internationalisation,

**PATRICE GARNIER**

CEO at Amabiotics



Dr. Patrice Garnier is Chief Executive Officer for Amabiotics, a biopharmaceutical company that develops innovative diagnostics and microbiome-derived medicines to fight age-related diseases with a strong research focuses on gut-brain axis pathologies, metabolic disorders and oncology. Dr. Garnier is an entrepreneur with 20 years of experience leading high-tech companies. Prior to joining Amabiotics in 2013, he founded and served for 9 years as CEO in a bioinformatics company that delivers genome to metabolome solutions for data analysis and management. He also co-founded IgenBio. Dr. Garnier holds an MSc in quantum physics from the École Normale Supérieure in Paris. He completed his PhD in nanotechnology in Professor Catherine Brechignac's group at the Laboratoire Aimée Cotton, CNRS.

**WOUTER DE JONGE**

Professor of Neurogastroenterology at AMC, CoFounder of Gut Research



Professor Wouter de Jonge received his doctoral training at University of Utrecht, and Columbia University, and received his Phd in 2001 (Medicine, University of Amsterdam and Maastricht). He took up postdoctoral positions at the AMC in Amsterdam and Oxford University. He chairs the gastro-intestinal research group at the AMC since 2013 and holds a part time W2 professorship at the Dept of Surgery at the University of Bonn, Germany. He is currently coordinating a Marie Curie industrial training network (EpiMac) aimed at understanding epigenetic marks that shape differentiation of inflammatory cells. He is working with the Galvani Bioelectronics network consortium since 2014, served on the board of the scientific committees a.o. national trust for Gastro Intestinal and Liver Diseases, and is founder of the spin off company Gut-research Services.

**MARION SOTO**

Project leader at LNC Therapeutics



Dr. Marion Soto is leader of a project targeting the gut-brain axis at LNC Therapeutics. After graduating from the Ecole Polytechnique in Paris, she earned a Ph.D. in Nutrition and Neurobiology in 2014 from AgroParisTech in France. Marion was then a fellow in C. Ronald Kahn Laboratory at Joslin Diabetes Center, Harvard Medical School. Marion research at Harvard combined both basic science investigations and translation into clinical research, using several MRI techniques in patients with type 2 diabetes to understand how this pathology affects brain function. Her research interests also focused on how the modulations in microbiome composition associated with type 2 diabetes and obesity lead to insulin resistance in the brain and to defects in metabolism, cognition and behavior.

**PHILIP STRANDWITZ**

Co-Founder and CEO at Holobiome



Dr. Philip Strandwitz is a specialist in the microbiome, with a focus on the gut-brain-axis. Philip received his PhD in Biology under the guidance of Dr. Kim Lewis at Northeastern University, where he focused on cultivating unique bacteria from the human gut microbiota, as well as studying their ability to modulate neurotransmitters. Since assembled a broad range of clinical and academic collaborators to further profile the link between the human microbiome and the gut-brain-axis. He is now CEO at Holobiome, a company he co-founded to translate microbiome science into novel therapeutics to treat diseases of the central and enteric nervous systems.

BIOGRAPHIES

**SHAHRAM LAVASANI**

Founder and CEO at ImmuneBiotech AB



Shahram Lavasani holds a Ph.D. degree from Lund University in Medical Inflammation Research where he studied the immunoregulation and novel immunotherapies in multiple sclerosis (MS). He is a skillful immunologist, with many years of teaching and research expertise on gastrointestinal complications in autoimmune and chronic inflammatory diseases. Focusing on Gut-Brain axis he has pioneered research in MS, which is an autoimmune disease of the central nervous system, by demonstrating inflammation and increased permeability in the gut and introduced microbiota-based therapies using combination of probiotic bacteria. He is the founder of ImmuneBiotech, developed a proprietary lactobacilli library and established accurate and multiple selection technologies to screen and design formulations for the optimal therapeutic management of the diseases.

**MAGALI CORDAILLAT-SIMMONS**

Scientific and Regulatory Affairs Director at Pharmabiotic Research Institute (PRI)



Dr. Cordaillat-Simmons works as the Scientific and Regulatory Affairs Director at the Pharmabiotic Research Institute (PRI), located in France. The PRI is a non-profit association dedicated to supporting companies in the development and registration of Microbiotic Medicinal Products as drugs in Europe. There she supervises the association's analysis of the European pharmaceutical legislation, as well as the association's Regulatory Strategy and supports the PRI member-companies in their interactions with the national and European drug authorities.

**GEORGE WEINSTOCK**

Professor, Director of Microbial Genomics at Jackson Laboratory



Dr. George Weinstock is the Evnin Family Professor and Director of Microbial Genomics at the Jackson Laboratory for Genomic Medicine where he established a group devoted to genomic studies of infectious diseases and the human microbiome. Dr. Weinstock's group has played a leading role in the NIH Human Microbiome Project, both Phase 1 and 2, with both basic science and clinical studies, and his current research follows on those themes. Dr. Weinstock has worked in genomics and microbiology for over 40 years. Previously, he was the co-director of the Human Genome Sequencing Center at Baylor College of Medicine in Houston where he was one of the leaders of the Human Genome Project. He has also been an innovator in methods for microbial genetics, application of DNA sequencing in genomics, and software for genome analysis, as well as medical and agricultural applications of genomics. His research continues evolving with new issues in DNA sequencing technology.

REGISTRATION FORM

PACKAGE NAME

Title:
Name:
Position:
E-mail:

Title:
Name:
Position:
E-mail:

Company:
Address:
City:
VAT No:
Signature:

Postcode:
Phone
Date: - -
 dd mm yyyy

This booking is invalid without signature

Diogo Lino Ribeiro
Project Director, Europe | Porto Office
EM: diogo.ribeiro@epmgroup.org
PH: +351 915 239 640

Hotel Address:
Le Méridien Etoile Paris
Boulevard Gouvion-Saint-Cyr, 75017 Paris
France

ACADEMIC/ MED./ NPO PACKAGE
Individual or Group Registration

2 days Summit ✓

Full-Access to All Sessions ✓

Coffee Breaks/Lunches ✓

Gala Dinner (Extra 50€) ✓

Unique 1-on-1 meetings ✕

Airport Pick-Up/Drop-Off ✕

Accommodation at the Hotel Venue ✕

INDUSTRY BASIC PACKAGE
Individual Registration

2 days Summit ✓

Full-Access to All Sessions ✓

Coffee Breaks/Lunches ✓

Gala Dinner ✓

Unique 1-on-1 meetings ✓

Airport Pick-Up/Drop-Off ✕

Accommodation at the Hotel Venue ✕

INDUSTRY PREMIUM PACKAGE
Individual Registration

2 days Summit ✓

Full-Access to All Sessions ✓

Coffee Breaks/Lunches ✓

Gala Dinner ✓

Unique 1-on-1 meetings ✓

Airport Pick-Up/Drop-Off ✓

Accommodation at the Hotel Venue ✓

Team Discounts	Until June 29	After June 29
2 Delegates	5%	-
3 Delegates	10%	5%
4+ Delegates	15%	10%

By sending this form, I confirm that I have read and accepted the terms and conditions detailed below.

Confirmation

We will confirm your participation after receiving the signed registration form the delegate will receive the invoice within 24h of sending the signed form. The hotel details will be sent 2 or 3 weeks before the start of the conference.

Cancellations

Cancellations made one month prior to the start of the conference will be refunded less 50% administration charge. Refunds will be made after the conference. Cancellations made within one month of the conference start date will receive no refund. Substitutes are accepted up to 3 days before the conference. Any cancellation will be accepted latest one month before the event and should be informed in written form.

Force Majeure

While every reasonable effort will be made to adhere to the advertised package, EPM Group reserves the right to change event dates, sites or location, omit event features, or merge the event with another event as it deems necessary without penalty and in such situations no refunds, part refunds or alternative offers shall be made (including, but not limited to any force majeure occurrence) and provided that the event is not postponed to a later date nor is it merged with another event, the client shall receive a credit note for the amount that the client has paid to such permanently canceled event. No refunds, part refunds or alternative offers shall be made.

Copyright

All Intellectual Property rights in all materials produced or distributed by EPM Group in connection with this event are expressly reserved and any unauthorized duplication, publication or distribution is prohibited.

All Prices displayed include VAT @ The VAT amount will be displayed after the payment process and shown on your invoice.

SPONSORSHIP PACKAGES

PLATINUM SPONSOR

10,000€

General:

- › Logo on conference website (with link to company website);
- › Opportunity to write an article in our website blog;
- › Online promotion on all our social networking sites;

Conference:

- › Opportunity to speak at the conference (according to availability);
- › One page (A4) color advertisement in the conference agenda;
- › Company flyers inserted in delegate bags;
- › Sponsoring of Gala Dinner (Logo on the menu);

Exhibition space: 6m² (chairs and table included)

One-on-one meetings: 30min (unlimited meetings)

Registrations included: 6 Basic Package

GOLD SPONSOR

8,000€

General:

- › Logo on conference website (with link to company website);
- › Opportunity to write an article in our website blog;
- › Online promotion on all our social networking sites;

Conference:

- › Opportunity to speak at the conference (according to availability);
- › One page (A4) color advertisement in the conference agenda;
- › Company flyers inserted in delegate bags;

Exhibition space: 6m² (chairs and table included)

One-on-one meetings: 30min (unlimited meetings)

Registrations included: 5 Basic Package

SILVER SPONSOR

6,500€

General:

- › Logo on conference website (with link to company website);
- › Opportunity to write an article in our website blog;
- › Online promotion on all our social networking sites;

Conference:

- › Opportunity to speak at the conference (according to availability);
- › ½ page (A4) color advertisement in the conference agenda;
- › Company flyers inserted in delegate bags;

Exhibition space: 6m² (chairs and table included)

One-on-one meetings: 30min (unlimited meetings)

Registrations included: 4 Basic Package

BRONZE SPONSOR

4,500€

General:

- › Logo on conference website (with link to company website);
- › Opportunity to write an article in our website blog;
- › Online promotion on all our social networking sites;

Conference:

- › Company flyers inserted in delegate bags;

Exhibition space: 6m² (chairs and table included)

One-on-one meetings: 30min (unlimited meetings)

Registrations included: 3 Basic Package

EXHIBITION SPACE

3,000€

General:

- › Logo on conference website (with link to company website);
- › Online promotion on all our social networking sites;

Exhibition space: 6m² (chairs and table included)

One-on-one meetings: 30min (unlimited meetings)

Registrations included: 2 Basic Package

COFFEE BREAK/LUNCH SPONSOR

2,000€

Conference:

- › Company Roll-up (to be supplied by sponsor)

One-on-one meetings: 30min (unlimited meetings)

Registrations included: 1 Basic Package

ADDITION SPONSORSHIP PACKAGES

(contact us for more information)

- › Conference Delegate Bag Sponsor;
- › Posters Prizes Sponsor;
- › Scientific Topic Sponsor.

Click below to register as a sponsor

ONLINE REGISTRATION

